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Abstract
Background: Successful management of cardiovascular disease (CVD) is impaired by poor adherence to clinical
practice guidelines. The objective of our review was to synthesize evidence about the effectiveness of interventions
that target healthcare providers to improve adherence to CVD guidelines and patient outcomes.
Methods: We searched PubMed, EMBASE, Cochrane Library, PsycINFO, Web of Science and CINAHL databases from
inception to June 2014, using search terms related to adherence and clinical practice guidelines. Studies were limited
to randomized controlled trials testing an intervention to improve adherence to guidelines that measured both a
patient and adherence outcome. Descriptive summary tables were created from data extractions. Meta-analyses were
conducted on clinically homogeneous comparisons, and sensitivity analyses and subgroup analyses were carried out
where possible. GRADE summary of findings tables were created for each comparison and outcome.
Results and Discussion: We included 38 RCTs in our review. Interventions included guideline dissemination,
education, audit and feedback, and academic detailing. Meta-analyses were conducted for several outcomes by
intervention type. Many comparisons favoured the intervention, though only the adherence outcome for the
education intervention showed statistically significant improvement compared to usual care (standardized mean
difference = 0.58 [95 % confidence interval 0.35 to 0.8]).
Conclusions: Many interventions show promise to improve practitioner adherence to CVD guidelines. The quality of
evidence and number of trials limited our ability to draw conclusions.
Keywords: Clinical practice guidelines, Cardiovascular disease, Adherence, Systematic review
Background
Cardiovascular disease (CVD) is a leading cause of death
in Canada [1]. Successful management of CVD involves
not only the treatment of a specific disease, but also treat-
ing and preventing risk factors for CVD, including dia-
betes, dyslipidemia and hypertension [1–3]. However, the
management of CVD is complicated by the large number
of clinical practice guidelines available for conditions that
contribute to this disease. An article by Ray et al. noted
there are also discrepancies in recommendations across
guidelines, potentially contributing to low adherence rates
[2, 4, 5]. A harmonized guideline by Tobe et al. (2011)
found there are over 400 recommendations for managing
risk factors for heart disease [3].
Given the complexity of the management of this illness,
it is imperative that practitioners use guidelines, and the
most appropriate guidelines, in caring for patients with
CVD and risk factors for CVD. The impact of guideline
implementation has been illustrated previously; a review
by Grimshaw and Russell found that using guidelines im-
proved clinical practice [6]. Despite evidence to support
the use of guidelines, there remains a gap in their imple-
mentation [7].
The dissemination of guidelines alone has little to no
effect on practice [8], thus many studies have investi-
gated interventions of varying intensity to increase the
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uptake of clinical practice guidelines. Numerous studies
of interventions to improve the uptake of guidelines in
CVD prevention are available. However, their overall im-
pact on guideline adherence and clinical outcomes is
unclear. Unverzagt et al. [9] published a systematic
review on a similar topic that focused on primary care
physicians’ adherence to guidelines, wherein they dem-
onstrated these interventions can have an impact on
adherence outcomes. It is important to determine the
effect of these interventions on other healthcare pro-
viders, as well as determine the impact of these interven-
tions on clinical outcomes, which is yet to be addressed
in the literature to our knowledge.
We identified and synthesized the available research evi-
dence about the effectiveness of interventions that target
healthcare providers to improve adherence to CVD pre-
vention and treatment guidelines and clinical outcomes.
Our secondary objective was to explore characteristics of
guideline implementation interventions and contexts that
are associated with increased effectiveness. This leads to
our research question: what is the most effective interven-
tion to improve the implementation of, uptake of, or
adherence to cardiovascular disease-related clinical prac-
tice guidelines by healthcare providers in randomized
controlled trials?
Methods
As this research did not involve the collection of primary
data, we did not seek ethics approval. This review has




A systematic search was conducted using search terms re-
lated to “adherence” and “clinical practice guidelines”,
which was refined with the help of a medical librarian. We
searched the following databases: PubMed, EMBASE,
Cochrane Library (including CENTRAL, DARE and
HTAs), PsycINFO, Web of Science and CINAHL (all
available years, up to June 2014). Grey literature was also
searched, including clinicaltrials.gov to identify potential
new studies, ICTRP registry database, and ProQuest thesis
database. Our search strategy did not impose any limits
on language of publication (Additional file 1).
Inclusion criteria
Study design
The included studies were limited to randomized
controlled trials (RCTs). We included all types of RCTs,
including cluster RCTs, and nested designs.
Population
Studies that enrolled any registered healthcare providers
were included. Subgroups of interest for our analyses in-
cluded comparing physician participants to other health-
care providers (non-physicians). We excluded trials if less
than 75 % of the participants included were certified, regu-
lated healthcare providers.
Intervention
All studies that evaluated the impact of an intervention
on the implementation of, uptake of, or adherence to a
clinical practice guideline by a health care provider were
included. The guideline of concern had to relate to the
prevention or management of CVD, including risk factor
management for any of: diabetes, dyslipidemia or hyper-
tension. Guideline definitions were based on authors
stating a guideline to be such. A study was deemed to be
about the implementation or adherence to a guideline if
the trial report explicitly stated that improving use of a
clinical practice guideline was the focus of the interven-
tion. Types of interventions included: academic detail-
ing, audit and feedback, educational sessions, continuing
medical education (CME) sessions, and ‘other’ (such as
reminders or decision support systems).
Comparison group
We selected studies that included at least one control
group. Comparison groups included usual care, a similar
guideline implementation intervention of differing inten-
sity or duration than the main intervention group, or no
intervention (receipt of the intervention at a different
time than the intervention group, such as after data
collection).
Primary outcomes
We included trials that reported both a measure of
guideline adherence and at least one clinical outcome.
Measures of adherence included self-reported adherence,
prescription review, and chart review. We included stud-
ies reporting any relevant clinical outcomes and consid-
ered the following groups of outcomes for analyses:
mortality, hospitalizations, quality of life, and disease tar-
gets. Outcomes assessed at similar time points were com-
bined in our analysis as short term (3–6 months), and
long term (7 months or longer).
Study selection and data extraction
Articles were screened based on title and abstract using
the inclusion criteria, then based on full text by two in-
dependent reviewers. Discrepancies were resolved by
consensus.
Data from included articles was extracted in duplicate
by independent extractors. We extracted study character-
istics (study design, setting and population), a description
Jeffery et al. BMC Family Practice  (2015) 16:147 Page 2 of 15
of the intervention (the type of intervention, providers,
and resources involved), comparison intervention, risk of
bias, outcome measurement and results, and funding for
the study. Risk of bias was assessed using the Cochrane
Risk of Bias tool for RCTs [10]. All discrepancies between
extractors were resolved through consensus. Data was
managed using spreadsheets created for each extractor.
Authors were contacted after data extraction and consen-
sus meetings were completed to request missing data and
to check the accuracy of our extractions.
Data analysis
We conducted descriptive analyses of included studies.
We conducted meta-analyses (MA) for outcome results
when there was sufficient clinical homogeneity across
the studies. Clinical homogeneity was based on similar
study characteristics (intervention type, outcome and
follow-up point of interest). Meta-analyses were con-
ducted in Review Manager (RevMan 5), using a random
effects model and forest plots were generated. Intraclass
correlation coefficient (ICC) for cluster RCTs were used
in our meta-analyses to calculate the effective sample
size to ensure the effect of clustering was taken into ac-
count in our analyses, as per the Cochrane Handbook
[11]. A Z-test was used to assess statistical significance
of meta-analysis results and a p < 0.05 was considered
significant.
The adherence and patient outcomes were measured
as both dichotomous and continuous outcome measures.
Odds ratios (OR) and 95 % confidence intervals (CI)
were calculated for use in the MA for dichotomous out-
comes. Standardized mean differences (SMD) were used
for continuous outcomes, as outcomes measuring the
same construct were measured on different scales. Most
continuous outcome analyses looked at the differences
in mean change of each group from baseline, and this
value was used in the MA, though some trials reported
follow up results in each group, wherein we calculated
the change score for each group to use in our MA. In
order to impute the standard deviation for the change
score in this instance, the standard deviation of the
change score from another similar study was used.
We conducted sensitivity analyses to determine the ro-
bustness of our results, comparing the results of our
analyses including and excluding studies with imputed
standard deviations, and excluding studies with high risk
of bias (greater than 3 domains rated as high risk of
bias). We conducted subgroup analyses considering par-
ticipant subgroups (physician participants and other
healthcare providers), and considering the condition that
was the focus of the guideline in the study (acute and
chronic CVD conditions or risk factors). We planned to
create funnel plots to investigate potential publication
bias if at least ten studies were included for a given
outcome, however this was not possible. We present a
summary of the overall strength of evidence available
using GRADE Summary of Findings tables produced
using GRADEpro.
Results
Results of the search
We identified 12,255 potentially relevant unique citations.
We excluded 12,033 citations during the initial abstract
and title screening. We reviewed 222 full text publications
and included 38 studies in the review [12–54] (Fig. 1).
Included studies (Table 1)
Eighteen studies took place in the USA, 14 were com-
pleted in Europe (the Netherlands, Italy, England, and
Norway), two took place in Canada, one in South Africa,
one in Brazil, one in Asia-Pacific area, and one in the
Virgin Islands. Thirty-five studies included an interven-
tion to improve physician use of guidelines and ten of
those studies included a nurse as a target for the inter-
vention; two studies focused on nurses alone, and one
study focused on pharmacists. The most common inter-
vention type was educational focused intervention (18/38),
followed by audit and feedback (9/38), academic detailing
focused interventions (4/38), comprehensive interventions
that included education, audit and feedback and an
academic detailing component (2/38), and “other” inter-
ventions that did not fall into any pre-designated category
(8/38). Seven trials included more than one intervention
group. All studies included an adherence outcome, as per
our inclusion criterion. Disease target was the most com-
mon clinical outcome reported (33/38 trials), followed by
mortality (11/38). Hospitalization and quality of life data
were also reported in 8/38 and 6/38 trials, respectively.
Risk of bias in included studies
Risk of bias summary graphs and tables were created
using RevMan (Figs. 2 and 3). Risk of bias was often
assessed as unclear due to poor reporting of a methodo-
logical procedure. The majority of trials (33/38) were
cluster RCTs, therefore additional risk of bias criteria
were included for these studies. Random sequence gen-
eration was most often assessed to be low risk of bias,
while blinding of participants was most commonly rated
as high risk of bias.
Effects of interventions
Education intervention
Seventeen trials tested an education-focused interven-
tion and were included in a meta-analysis. These trials
overall favoured the intervention, and one meta-analysis
was statistically significant. Seven trials (2545 subjects)
reported mortality outcomes, three of which reported
mortality at a short term time point with an overall odds
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ratio of 0.54 (95 % CI 0.2 to 1.42). Four trials reported mor-
tality at a long term time point with an overall odds ratio
of 0.48 (95 % CI 0.11 to 1.98). Four trials (979 subjects)
reported hospitalizations as an outcome at a long term
time point. The overall odds ratio for this outcome was
0.88 (95 % CI 0.54 to 1.41). Six trials (2145 subjects)
reported disease target results at a short term time point
(SMD = −0.32 (95 % CI −0.71 to 0.07)) and five trials
(2732 subjects) reported this outcome at a long term
time point (SMD = −0.09 (95 % CI −0.24 to 0.07))
(Fig. 5). Seventeen trials reported adherence outcome
data, six (2306 subjects) reported dichotomous data at a
short term time point (OR = 2.11 (95 % CI 0.90 to 4.97)),
four trials (322 subjects) reported continuous data at a
short term time point (Fig. 4) and eight trials (6019 sub-
jects) reported dichotomous data at a long term time
point (OR = 1.05 (95 % CI 0.82 to 1.34)) (Fig. 6).
Audit and feedback
Nine trials included an intervention that focused on
audit and feedback, and seven of those trials reported
data sufficient to be included in meta-analyses. Three
trials (2240 subjects) reported disease target results at a
long term time point with an overall effect of −0.44
SMD (95 % CI −1.05 to 0.17) (Fig. 5). Six trials (2983
subjects) reported adherence data at a long term time
point with an overall odds ratio of 1.39 (95 % CI 0.88 to
2.21) (Fig. 6).
Academic detailing
Four trials (6017 subjects) included academic detailing as
the focus of the intervention and all of these trials reported
data that was included in a meta-analysis for adherence
outcome. The overall odds ratio for this comparison was
1.32 (95 % CI 0.88 to 1.96) (Fig. 6).
Other interventions
Eight trials included an intervention whose focus did not
fit these previous groups. Four trials (1782 subjects) in-
cluded a decision support tool as the focus of their inter-
vention. The overall odds ratio for this comparison was
1.19 (95 % CI 0.83 to 1.70) (Fig. 6).
Sensitivity and subgroup analyses
Sensitivity analysis investigating the impact of imputed
standard deviations in continuous data was possible in
the education intervention outcome for the disease tar-
get outcome at a short term time point. The pooled
SMD from six studies in this comparison was −0.32
(95 % CI −0.71 to 0.07), while the estimate from the sensi-
tivity analysis, with studies that included imputed standard
deviation removed, was −0.27 (95 % CI −0.71 to 0.17). An-
other sensitivity analysis, investigating the impact of high
Fig. 1 PRISMA flow chart of study inclusions
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Table 1 Characteristics of included studies
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Table 1 Characteristics of included studies (Continued)
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risk of bias studies on the overall estimate was possible for
the meta-analysis of the effect of education on short term
adherence outcomes. The pooled odds ratio was 2.36
(95 % CI 0.86 to 6.51) before studies with high risk of bias
were excluded, and 3.65 (95 % CI 0.53 to 25.15) after stud-
ies with high risk of bias were excluded.
We compared results in studies that targeted physi-
cians only in their intervention to interventions that
involved non-physician healthcare providers alone or in
addition to physicians with subgroup analysis. This sub-
group analysis was possible in seven comparisons, and
the subgroups of physician participants alone frequently
had less heterogeneity than when grouped with all stud-
ies, suggesting participants may be a source of hetero-
geneity (Additional file 2: Figure S1). Another subgroup
analysis we conducted compared results in studies that
focused on an acute cardiovascular condition to a chronic
cardiovascular condition. Five comparisons showed incon-
sistent results although the heterogeneity was reduced in
at least one of the two subgroups in all comparisons.
GRADE summary of findings tables
The overall quality of evidence identified in this system-
atic review was moderate to very low due to high risk of
bias, imprecision, and heterogeneity (Table 2). The most
patient important outcome of mortality had moderate
quality of evidence associated, indicating the results may
be interpreted with some confidence.
Discussion
Statement of principal findings
We have focused on interventions aimed at improving
adherence to CVD guidelines. Overall studies are variable
in their conclusions on whether the intervention was
effective, though our quantitative analysis supports that
interventions trend towards having an impact on adher-
ence to guidelines and patient outcomes. One comparison
of an education intervention for the adherence outcome
was statistically significant, indicating this area of study
deserves further consideration, as these interventions may
help improve both adherence to guidelines, and more
importantly, patient outcomes. Our results were robust
where sensitivity analyses were possible. Subgroup ana-
lyses (participant and condition) reduced the statistical
heterogeneity but there was inconsistency in the subgroup
with the larger effect for each analysis. In some cases, the
physician subgroup favoured the intervention to a greater
degree than the non-physician subgroup, but in other
comparisons the opposite was true. The same results were
found for the condition subgroup (acute vs. chronic
condition). The confidence in these recommendations
ranged from moderate to very low based on a GRADE
summary of findings due to imprecision, risk of bias, and
inconsistency.
Fig. 2 Risk of bias summary table for each study. Green indicates a low
risk of bias, yellow indicates unclear risk of bias and red indicates high
risk of bias, as assessed by reviewers using the Cochrane risk of bias tool
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Strengths and weaknesses of the review
Our systematic review has several strengths, including
that it was comprehensive in inclusion of studies. We
included all types of healthcare providers in order to
illustrate the impact these interventions can have on
both physicians and non-physicians, which is increas-
ingly important for multidisciplinary teams required for
complex diseases such as CVD. We limited our study
inclusion to those that reported both adherence and a
patient outcome, as interventions must improve both in
order to be clinically useful. All screening, data extraction,
and risk of bias assessment was done in duplicate with
trained reviewers to ensure the reproducibility of these
results. Our quantitative analysis was pre-specified to
avoid finding spurious results due to post hoc analyses.
We minimized the number of comparisons that were
made while ensuring comparisons had fairly good clinical
homogeneity to maintain the strength of those conclu-
sions. We also contacted authors for missing data and to
verify the accuracy of our data extractions of their trial,
thus we have confidence in this data.
However, this review has limitations. The first relates
to the quality of reporting in trials. Reporting of risk of
bias domains was poor in many trials, making it diffi-
cult to assess risk of bias. There was also significant
heterogeneity in the studies’ interventions and charac-
teristics making combining results in a meta-analysis
difficult, leading to small numbers of studies included
in each comparison. Meta-analyzing results was further
complicated by uncertainty of the exact nature of some
interventions due to limited descriptions of interven-
tions available in publications. This also limited our
Fig. 3 Risk of bias summary graph, summarized for each domain. Green indicates a low risk of bias, yellow indicates unclear risk of bias and red
indicates high risk of bias, as assessed by reviewers using the Cochrane risk of bias tool
Fig. 4 Forest plot of education intervention comparison for continuous adherence outcome at a short term time point (<6 months)
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ability to assess publication bias, so we were unable to
determine the effect that might have on our confidence
in these results.
Comparison to similar reviews
A systematic review on CVD guideline implementation
strategies in primary care physicians by Unverzagt et al.
reported similar conclusions on the effectiveness of
education and reminder system interventions to im-
prove adherence [9]. Our review extends these findings,
illustrating the impact at the patient level on mortality,
hospitalizations, quality of life and disease targets, and
to different healthcare providers.
Similar to our findings, a review by Grimshaw et al.
on guideline implementation noted overall the most
effective interventions tend to include specific educa-
tional interventions and patient specific reminders at
point of care [6].
Meaning of the review results
These results indicate there is some evidence to support
the use of some interventions to improve healthcare
provider adherence to CVD guidelines. Despite the limi-
tations in the studies in this review, a trend of interven-
tions improving adherence and patient outcomes was
noted, supporting that these interventions may be more
effective than passive guideline dissemination strategies.
However, more studies are needed to strengthen these
conclusions.
The majority of interventions included were multifa-
ceted, which some reviews have suggested provide posi-
tive outcomes more frequently than single interventions
[53–55]. However, our results were not consistent with
these; we found these interventions have limited effects,
which may be related to the number of components in a
given intervention, as only two interventions included all
of the types of interventions. A review by Squires et al.
found there is ambiguity in the evidence of whether
multifaceted interventions are more effective than single
interventions, which is in agreement with our inconsist-
ent findings [55].
Another possible reason for the overall small effect
sizes may relate to the complexity of the management
of CVD. This includes treating and preventing multiple
Fig. 5 Summary disease target outcome forest plot for three comparisons measured by standardized mean difference, with point estimate and
95 % CIs
Fig. 6 Summary adherence outcome forest plot for five comparisons measured by odds ratio, with point estimates and 95 % CIs
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Table 2 Summary of findings table for educational interventions
Education compared to control for improving adherence to cardiovascular disease guidelines









Assumed risk control Corresponding risk Education (95 % CI) (studies) (GRADE)
Mortality Study population OR 0.54 2190 ⊕⊕⊕⊝
Follow-up: median 6 months 40 per 1000 22 per 1000 (0.2 to 1.42) (3 studies) moderatec
(8 to 56)
Moderate
26 per 1000 14 per 1000
(5 to 37)b





2145 ⊕⊝⊝⊝ SMD −0.32
(−0.71 to 0.07)
Follow-up: 3–6 months (6 studies) very lowc,e,f
(0.71 lower to 0.07 higher)




322 ⊕⊕⊕⊕ SMD 0.58
(0.35 to 0.8)
Follow-up: 6–24 months (4 studies) high
(0.35 to 0.8 higher)
Mortality Study population OR 0.48 355 ⊕⊕⊝⊝
Follow-up: 7 months - 10 years 182 per 1000 96 per 1000 (0.11 to 1.98) (4 studies) lowg
(24 to 306)
Moderate
146 per 1000 76 per 1000
(18 to 253)b
Hospitalizations Study population OR 0.88 979 ⊕⊕⊕⊕
Follow-up: 7–22 months 188 per 1000 170 per 1000 (0.54 to 1.41) (4 studies) high
(111 to 246)
Moderate
191 per 1000 172 per 1000
(113 to 250)b





2732 ⊕⊕⊝⊝ SMD −0.09
(−0.24 to 0.07)
Follow-up: 7–27 months (5 studies) lowf,h
(0.24 lower to 0.07 higher)
Adherence Study population OR 1.05 6019 ⊕⊕⊝⊝
Follow-up: 7–27 months 609 per 1000 620 per 1000 (0.82 to 1.34) (8 studies) lowc,i
(561 to 676)
Moderate
236 per 1000 245 per 1000
(202 to 293)b
Adherence Study population OR 2.36 2145 ⊕⊝⊝⊝
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risk factors in patients, such as diabetes, hypertension
and dyslipidemia [56]. Most guidelines address only
one of these diseases, and this may contribute to the
small improvements found in this review. Given the
multifactorial nature of CVD, it needs to be treated
with guidelines that acknowledge this. Using harmo-
nized CVD guidelines such as C-CHANGE is an im-
portant step that needs to be taken in CVD guideline
implementation intervention trials to ensure the best,
most comprehensive care is provided to patients [1].
This is also an important consideration as to why CVD
guideline implementation strategies must differ from
strategies used in treating simpler diseases such as
pneumonia or asthma [57, 58].
Unanswered questions and future research
It would be beneficial for more high quality studies on
this topic to be conducted to improve the strength of
our recommendations, given the low confidence in most
of these estimates due to a small number of studies
included in each MA. Interventions should be fully
described so they are not only reproducible, but future
reviews are able to confidently determine homogeneous
groups for meta-analyses. Future reviews on this topic
should also define clinically important differences to
determine whether the effects are not only statistically
significant, but clinically significant as well.
Conclusions
Interventions to improve adherence to CVD guidelines can
be effective at improving both adherence and patient out-
comes, and are often more effective than guideline dissem-
ination alone. Interventions that focused on healthcare
provider education demonstrated statistically significant
improvements. The overall quality of evidence available in
this review was low, but several patient important out-
comes including mortality were supported by moderate to
high quality evidence.
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Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
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